Immunogenicity

  1. Home

  2. caret-right icon

    Immunoassay Solutions

  3. caret-right icon

    Applications

  4. caret-right icon

    Clinical/Preclinical Research

  5. caret-right icon

    Immunogenicity

Fast, automated, and robust immunogenicity immunoassays with Gyrolab® platform

Assessment of anti-drug antibodies (ADAs) is a fundamental requirement of immunogenicity testing of biotherapeutics during preclinical or clinical studies. ADA immunoassays using plate-based methods can be extremely complex and require lengthy protocols to maximize drug tolerance, minimize drug interference and establish equilibrium, using methods such as overnight incubations and acid sample pretreatment.

Fast, automated, and robust immunogenicity immunoassays with Gyrolab platform

Accelerate immunogenicity screening in discovery, lead selection, or early preclinical with generic ADA assays:

Multiple antibody-based drug candidates are often evaluated in parallel using a small number of animals. The development of drug-specific ADA assays for each candidate can be impractical. However, a generic ADA assay that detects human IgG in complex with anti-human IgG in preclinical study samples can be used without assay development between drug candidates. Learn more about generic ADA assays for rodent and non-human primate studies on the Gyrolab platform.

Gyrolab Generic ADA sandwich assay
Explore Gyrolab Generic ADA Kits

Automate drug-specific ADA assays in preclinical or clinical studies:

Sandwich assays using a drug product capture antibody and labeled drug product for detection are typically used for drug-specific ADA assays for measuring free ADA. Gyrolab ADA Solution (Gyrolab Mixing CD 96 and Rexxip ADA Buffer) automates drug-specific free ADA assays using the Gyrolab Mixing CD 96 for automated or offline acid dissociation which is often required to dissociate immune complexes. 

Drug-specific sandwich ADA assay
View Gyrolab Mixing CD 96 in action

Read our White Paper: ADA — How to Maximize Drug Tolerance and Minimize Sample and Reagent Consumption

Dedicated Gyrolab ADA software with automated cutpoint analysis and designed for  21 CFR Part 11 compliance, facilitates data analysis for either screening or confirmatory results. Gyrolab systems ADA assays exhibiting high drug tolerance coupled with high sensitivity and consistent performance providing high-quality data.

How to Maximize Drug Tolerance and Minimize Sample and Reagent Consumption

To accelerate assay development, Gyrolab assay protocols are available to for mAbs and biosimilar therapeutics: View Gyrolab ADA assay protocols

Want to learn more? Speak to our scientists about your application.

Talk to Our Scientists

 

Explore real world examples 

Learn how Gyrolab is advancing research in your field. Find resources and insights to inform your work and keep you moving forward. 

Publications